ICCM IceCure Medical Ltd.
IceCure Medical Ltd. (ICCM) is expected to report earnings on February 17, 2027, before the market open. The consensus earnings estimate is a loss of $0.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on November 18, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About IceCure Medical Ltd.
IceCure Medical develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.
Sector
Healthcare
Industry
Medical Instruments/Supply
Charts powered in part by Lightweight Charts™ by TradingView.